The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
For decades, biopharmaceutical companies have developed new therapies using a cookie cutter approach to development and manufacturing. While there have been tremendous advances in science, patients still struggle with adherence and are challenged with medication access. In addition, daily pills do not optimize pharmacology in their delivery, such that patients suffer from the peaks and troughs in drug levels, which may impact safety and efficacy. Some of these challenges have even greater impact when considering global health issues like malaria eradication, safe contraception and HIV prevention and treatment. In the case of malaria, an oral treatment delivering drug for 2 weeks could lead to dramatically reduced disease transmission and potential eradication. Working in partnerships with organizations like the Gates Foundation and the NIH, an emerging new delivery platform representing one of the most significant advances in oral drug delivery may change all that. Replacing daily oral medications is possible through the development of an innovative drug delivery platform that delivers long-acting oral therapies that last for a week or as long as a month for a wide array of therapeutic areas. From the development of new technology that enables clinical work to be conducted in a lab setting, to state-of-the art continuous manufacturing that allows for flexible and efficient production, new science is changing the way therapies are developed and delivered by changing the pill and not the patient. The ability to optimize the way medicine is delivered has the potential to improve adherence and health outcomes while simplifying people’s lives around the world.